🔎 Trials Near Me

Почетна › Беркитов лимфом › Колорадо

Клинички испитувања за Беркитов лимфом во Колорадо

13 студии за Беркитов лимфом бараат учесници на локации во Колорадо.

Градови во Колорадо

Официјален текст на студијата (англиски)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital Colorado, Aurora
Се регрутираФаза 2
366 Days – 46 Years · Сите полови · Ажурирано 2.10.2026 · NCT06124157

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital Colorado, Aurora
Се регрутираНабљудувачка студија
Возраст од 0 до 38 · Сите полови · Ажурирано 1.10.2026 · NCT06131801

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's Hospital Colorado, Aurora
Се регрутираФаза 2
365 Days · Сите полови · Ажурирано 25.9.2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • CBCI, Colorado Blood Cancer Institute, Denver
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07648264

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora
Се регрутираФаза 1/2
6 Months – 25 Years · Сите полови · Ажурирано 17.9.2026 · NCT06395103

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

  • Children's Hospital Colorado, Aurora
Се регрутираФаза 1/2
31 Days – 30 Years · Сите полови · Ажурирано 14.9.2026 · NCT04544592

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Се регрутираФаза 2
Возраст од 1 до 30 · Сите полови · Ажурирано 1.9.2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Се регрутираФаза 3
365 Days – 25 Years · Сите полови · Ажурирано 25.8.2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Colorado Children's Hospital, Denver
Се регрутираФаза 2
Возраст од 7 до 25 · Сите полови · Ажурирано 19.8.2026 · NCT05082519

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Colorado Blood Cancer Institute, Denver
Се регрутираФаза 1/2
Возраст од 13 до 90 · Сите полови · Ажурирано 6.8.2026 · NCT06533579

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

  • Children's Hospital Colorado, Aurora
Се регрутираФаза 1
3 Months – 30 Years · Сите полови · Ажурирано 28.11.2025 · NCT06559189

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

  • University of Colorado - Aurora Cancer Center, Aurora
  • Sarah Cannon - Colorado Blood Cancer Institute, Denver
Се регрутираФаза 1/2
Возраст од 15 до 50 · Сите полови · Ажурирано 9.9.2025 · NCT04150497

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

  • Children's Hospital Colorado, Aurora
Се регрутираФаза 2
Возраст од 1 до 25 · Сите полови · Ажурирано 4.5.2025 · NCT03509961

Од ClinicalTrials.gov, податоци преземени 5.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.